Related Experiment Video

Updated: Jan 16, 2026

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

861

Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC

Vera Thiel1,2, Wiebke M Nadler1,2, Alexander Kerner1,2

  • 1German Cancer Research Center (DKFZ).

Pancreas
|September 26, 2025
PubMed
Abstract

Insights

This study reveals that CYP2S1 protein drives drug resistance in pancreatic cancer subtypes. Targeting CYP2S1 may improve chemotherapy effectiveness for pancreatic ductal adenocarcinoma (PDAC) patients.

Area of Science:

  • Oncology
  • Proteomics
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) exhibits molecular heterogeneity.
  • Understanding subtype-specific mechanisms of drug resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the proteomic profiles of distinct PDAC molecular subtypes.
  • To identify pathways involved in xenobiotic metabolism and drug resistance.
  • To assess the impact of these profiles on patient outcomes.

Main Methods:

  • Utilized serum-free PACO cell culture and MALDI/MS for proteomic profiling of PDAC subtypes.
  • Analyzed differential protein regulation in metabolic and drug resistance pathways.
  • Conducted knockdown and overexpression studies to determine the role of key proteins in drug resistance.

Main Results:

  • Proteomic analysis identified subtype-specific alterations in xenobiotic metabolism and drug resistance pathways.
  • CYP2S1 (a CYP450 family member) was upregulated in the HNF1A+ PDAC subtype.
  • Knockdown of AHR or CYP2S1 sensitized cells to SN38, while overexpression of CYP2S1 conferred resistance.

Conclusions:

  • CYP2S1 plays a significant role in mediating drug resistance in specific PDAC subtypes.
  • Targeting CYP2S1 and its regulatory pathways could enhance irinotecan efficacy.
  • These findings offer insights into PDAC subtype-specific drug resistance and potential therapeutic targets.
Keywords:
AHRCYP2S1GeLC-based MALDI/MSMSQBATPDAC

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.6K
Mapping Dysfunctional Protein-Protein Interactions in Disease09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

578

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
639
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
278